We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck’s COVID-19 pill Lagevrio (molnupiravir) not only reduced the risk of hospitalization or death in patients with mild-to-moderate COVID-19 by 32.1 percent, it also reduced the chance of needing acute care visits for weeks after treatment ended, researchers reported in the Annals of Internal Medicine. Read More
Roche subsidiary Genentech has filed a federal lawsuit claiming that Tanvex BioPharma’s not-yet-on-the-market biosimilar of Genentech’s blockbuster chemotherapy drug Herceptin infringes three patents. Read More
After getting deluged with more than 24,000 mostly negative comments about pharmacy benefit managers’ (PBM) effect on patients and payers, the U.S. Federal Trade Commission (FTC) has voted unanimously to investigate many of the PBMs. Read More
The settlement also prevents BMS from restricting Gilead Sciences from making or licensing a generic version of Evotaz (atazanavir and cobicistat), an HIV drug. Read More
The FDA’s Vaccines and Related Biological Products Advisory Committee voted almost unanimously yesterday for Emergency Use Authorization (EUA) of a two-dose primary series of the Novavax COVID-19 vaccine. Read More
Calling the results “a potential new standard-of-care” for pediatric brain tumors, Novartis said its chemotherapy combination of Tafinlar (dabrafenib) and Mekinist (trametinib) reduced the risk of disease progression or death in an ongoing study by 69 percent at 12 months, compared to standard chemotherapy. Read More
A former Eli Lilly employee is suing the drugmaker over allegations she was fired after identifying numerous production issues at Lilly’s Branchburg, N.J., plant, including in the manufacture of the company’s blockbuster, Trulicity. Read More
Johnson & Johnson (J&J) is pulling out of its COVID-19 vaccine supply contract with the troubled drug manufacturing plant, Emergent BioSolutions. Read More